Tata Group to launch COVID-19 test Feluda

The Drug Controller General of India (DCGI) gave endorsement for the business launch of India’s originally Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Covid test ‘Feluda’, created by the Tata Group and CSIR-IGIB (Institute of Genomics and Integrative Biology).

“This test utilizes an indigenously created, front line CRISPR innovation for discovery of the genomic succession of SARS-CoV-2 infection. CRISPR is a genome-altering innovation to diagnosing sicknesses,” said the release.

According to an official release gave Ministry of Science and Technology, The Tata CRISPR test, fueled by CSIR-IGIB, got administrative endorsements from DCGI for business launch, according to ICMR rules, meeting great benchmarks with 96% sensitivity and 98% specificity for recognizing the novel Covid-19.

“The Tata CRISPR test is the world’s first demonstrative test to deploy an extraordinarily adjusted Cas9 protein to effectively detect the infection causing Covid-19,” it included.